secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2026-06-02T12:00:36+00:00
Accession:  0001193125-26-252544
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Afrezza for pediatric diabetes patients ages 6+
------------------------------------------------------------

- FDA approved supplemental BLA for Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.
- More than 350,000 U.S. children and adolescents live with diabetes; majority have type 1 and require lifelong insulin.
- Approval fulfills the last postmarketing requirement from the original June 27, 2014 approval letter.
- MannKind expects to expand the patient population for Afrezza beyond adults.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/0001193125-26-252544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/mnkd-20260529.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-252544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer